Content about Hae

December 12, 2012
ViroPharma launches hereditary angioedema campaign

Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.

EXTON, Pa. — Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.

The company announced Wednesday the launch of the unbranded campaign focused on hereditary angioedema, particularly the emotional and psychological burden faced by patients with the disease, which results from deficiency of the human plasma protein C1 inhibitor and causes attacks of swelling and pain.

August 26, 2011
FDA approves Shire autoimmune disorder drug

The Food and Drug Administration has approved a drug made by Shire for a rare autoimmune condition, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Shire for a rare autoimmune condition, the agency said.

The FDA announced the approval of Firazyr (icatibant) for acute attacks of hereditary angioedema in patients ages 18 years and older. HAE, which affects fewer than 30,000 people in the United States, results from improper function of C1 inhibitor, a protein that regulates how certain immune system and blood clotting pathways function.